Dysgeusia News and Research

RSS

Short-term outcomes in pregnant patients with COVID-19 who received nirmatrelvir–ritonavir treatment

Researchers investigated the short-term outcomes of treating pregnant patients exhibiting mild to moderate symptoms of COVID-19 with Paxlovid, which is a combination of the antivirals nirmatrelvir and ritonavir.

15 Nov 2022

Exploring the safety and immunogenicity of KD-414, a novel SARS-CoV-2 vaccine

In a new study, researchers assessed the immunogenicity and safety of KD-414, an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

1 Nov 2022

Longitudinal cohort study of primary healthcare workers reveals long-lasting SARS-CoV-2 humoral immunity in the absence of vaccination

Researchers performed a longitudinal cohort study to assess the levels of immunoglobulins M (IgM), G (IgG), and A (IgA) against the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Oct 2022

Danish study shows 3rd booster dose reduces risk of long-COVID

A recent study posted to the medRxiv* preprint server found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the Omicron variant predominant period was associated with post-acute symptoms of coronavirus disease 2019 (COVID-19) or ‘long COVID’, as well general health problems with new onset – four months after a COVID-19 positive test result.

17 Oct 2022

Increased TMPRSS2 expression in tongue tissue of females and alcohol drinkers identified as a potential risk factor for SARS-CoV-2 infection

Researchers explored the association between the expressions of the ACE-2 receptor and TMPRSS2 in the tongue tissue and dysgeusia during SARS-CoV-2 infections.

17 Oct 2022

What is the association of SARS-CoV-2 vaccination with the risk of PASC in patients with SARDs?

Findings of a new study depicted that fully vaccinated patients suffering from systemic autoimmune rheumatic diseases harbor a lower propensity to developing long COVID symptoms compared to SARDs patients who are not fully vaccinated.

11 Oct 2022

Study shows astrocytes as breeding grounds of SARS-CoV-2 during brain infection

Researchers evidenced the presence of SARS-CoV-2 in the human brain, infecting astrocytes and impairing neuronal function and viability.

15 Aug 2022

How common is chronic fatigue syndrome among patients with long COVID-19?

In a new study, researchers found that myalgic encephalitis/chronic fatigue syndrome (ME/CFS) was common in long COVID-19.

10 Aug 2022

The possible immune-mediated mechanisms causing CNS alterations during and post-acute SARS-CoV-2 infection

In a recent review published in Immunity, researchers explored potential mechanisms of neuro-immune pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

22 Jun 2022

Profound neuroinflammation associated with long COVID

Around 36 to 53% of coronavirus disease 2019 (COVID-19) patients develop persistent chronic symptoms, often referred to as long COVID or PASC.

7 Jun 2022

Neurological symptoms may persist for over one year in long-COVID patients

Patients who have recovered from COVID-19 are likely to experience persistent neurologic symptoms for a median of 14.8 months following their initial infection.

30 May 2022

Prevalence of long COVID-19 after Omicron infection

A recent article posted to the medRxiv* preprint server analyzed the long coronavirus disease (COVID) linked with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

18 May 2022

What are the long-term symptoms of SARS-CoV-2 infection?

Researchers determines whether some symptoms of long-COVID are more specifically associated with SARS-CoV-2 infection than other conditions.

4 Apr 2022

Long COVID symptoms in families a year after SARS-CoV-2 infection or household exposure

A new study has analyzed symptoms up to one year of post-acute COVID-19 infection.

10 Mar 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Research team examines the prevalence of taste loss in COVID-19 patients

Reports of taste loss, a symptom of COVID-19, have been on the rise over the last two years. The taste dysfunction comes in different forms, including ageusia (total taste loss), hypogeusia (partial taste loss), and dysgeusia (taste distortion).

15 Feb 2022

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022

Dizziness is a common symptom of COVID-19

New research published in Internal and Emergency Medicine discusses the relationship between SARS-CoV-2 infection and dizziness.

6 Feb 2022

Study reveals seven major determinants of mortality risk for patients with COVD-19 and thoracic cancer

The risk of death for patients with SARS-CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

1 Feb 2022

Patients undergoing neurosurgical operations with concomitant COVID-19 infection have higher rates of perioperative complications

This unique paper compares neurosurgical patients with COVID-19 for perioperative complications to those without COVID-19.

31 Jan 2022